Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Feature|Podcasts|May 7, 2026
Strengthening the Generic Drugs Supply Chain
Author(s)Mike Hollan, Natalie de Graaf
Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.
Advertisement
In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain. The report details various areas where the national generic supply chain is weak and various ways that it can be strengthened.
Natalie de Graaf, VP and GM of data, AI, and machine learning and solutions for health and national security at the API Innovation Center, spoke with Pharmaceutical Executive about the report’s findings. The conversation touched on the following points:
- What data-driven approach is the API Innovation Center using to assess supply chain fragility?
- How can the US work with allies to reduce foreign drug dependency?
- What are the most fragile drug classes in the US supply chain?
Advertisement
Related to this article
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5